The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis
Javier Ampuero, R. Aller, Rocío Gallego‐Durán, Javier Crespo, José Luís Calleja, Carmelo García‐Monzón et al. · 2024 · 15 citationsRead the paper
BACKGROUND: MASLD can manifest as hepatocellular damage, which can result in mild elevation of aminotransferases. However, in some patients, MASLD presents with cholestatic pattern. OBJECTIVE: To assess the impact of the biochemical pattern on the natural course of MASLD, including liver damage in histology, the accuracy of non-invasive tests(NITs), and prognosis. METHODS: Multicenter study enrolling 2156 patients with biopsy-proven MASLD, who were classified based on their[ALT/ULN)]/[(ALP/ULN)] levels at the time of biopsy: (a) hepatocellular pattern(H), > 5; (b) mixed pattern(M),2-5; (c) cholestatic pattern(C), < 2. OUTCOMES: (a) histological evaluation of the single components of NAS, MASH, and fibrosis; (b) NITs and transient elastography assessing advanced fibrosis; (c) prognosis determined by the appearance of decompensated cirrhosis and death. RESULTS: Out of the 2156 patients, 22.9% exhibited the H-pattern, whilst 31.7% exhibited the C-pattern. Severe steatosis, ballooning, lobular inflammation, and MASH (56.4% H vs. 41.9% M vs. 31.9% C) were more common in H-pattern (p = 0.0001),whilst C-pattern was linked to cirrhosis (5.8% H vs. 5.6% M vs. 10.9% C; p = 0.0001). FIB-4(0.74(95% CI 0.69-0.79) vs. 0.83 (95% CI 0.80-0.85); p = 0.005) and Hepamet Fibrosis Score(0.77 (95% CI 0.69-0.85) vs. 0.84 (95% CI 0.80-0.87); p = 0.044)exhibited lower AUROCs in the H-pattern. The C-pattern[HR 2.37 (95% CI 1.12-5.02); p = 0.024], along with age, diabetes, and cirrhosis were independently associated with mortality. Most patients maintained their initial biochemical pattern during the second evaluation. CONCLUSIONS: The H-pattern exhibited greater necro-inflammation in the histology than the C-pattern, whereas the latter showed more cirrhosis. The accuracy of NITs in detecting fibrosis was decreased in H-pattern. The occurrence of decompensated events and mortality was predominant in C-pattern. Therefore, identifying MASLD phenotypes based on the biochemical presentation could be relevant for clinical practice.
What the full text shows
Tested in real conditions- The cholestatic pattern is independently associated with higher mortality. — HR 2.37 (95% CI 1.12-5.02) (Multivariate analysis including age, T2DM, and cirrhosis)
- The cholestatic pattern is linked to a higher risk of cirrhosis compared to hepatocellular or mixed patterns. — OR 2.77 (95% CI 1.54-4.99) (Biopsy-proven MASLD)
- The hepatocellular pattern is associated with higher rates of MASH. — 56.4% H vs. 41.9% M vs. 31.9% C (Biopsy-proven MASLD)
- Non-invasive tests (NITs) for advanced fibrosis are less accurate in patients with a hepatocellular pattern. — FIB-4 AUROC 0.74 (H) vs 0.83 (non-H); HFS AUROC 0.77 (H) vs 0.84 (non-H) (Predicting advanced fibrosis)
- The hepatocellular pattern is associated with more severe steatosis, ballooning, and lobular inflammation. — Severe steatosis: 28.3% H vs 9% C; Ballooning: 68.8% H vs 51.8% C; Inflammation: 77.7% H vs 62% C (Biopsy-proven MASLD)
- Setup
- 2156 patients from the Spanish HEPAmet Registry with biopsy-confirmed MASLD; mean follow-up of 4.6 years.
- How
- A multicenter observational study classified 2156 biopsy-proven MASLD patients into hepatocellular, mixed, or cholestatic patterns based on the ratio of ALT/ULN to ALP/ULN. The study analyzed histological components, the accuracy of non-invasive tests (FIB-4, HFS, NFS, transient elastography), and longitudinal prognosis (decompensation and death).
- Limitations
- Some patients were excluded from longitudinal analysis due to clinical trials or bariatric surgery (n=380). · Complete-case analysis was used for missing data, which may introduce bias.
Summarized by Gemma 4 from the open-access full text · 13 Oct 2026. Read it